PROSPECTIVE STUDY OF RELAPSE PREDICTORS IN PANIC DISORDER

恐慌症复发预测因素的前瞻性研究

• 批准号: 7380525
• 负责人: JACK M. GORMAN
• 金额: $ 0.54万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-17 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7380525
• 关键词: brain; fear; panic disorder; respiratory function

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The etiology of panic disorder remains unknown. Yet a convergence of data from neuroscience research on fear and clinical research on anxiety suggests panic disorder may be explained by a combination of genetically determined hypersensitivity of the brains fear pathways and the influence of stressful life events. There is also abundant evidence from both animal and human studies that stressful life events can impact on functioning of the brain's fear pathways and are associated with development, onset, and relapse of panic disorder. We have previously demonstrated significant abnormalities in cardiovascular and respiratory function measures in individuals with panic disorder. The control of the heart and lungs is affected by regions of the brain involved in the response to stress and the development of anxiety. We now plan to investigate the relationships of stressful life events, the brain's control of cardiovascular and respiratory function, and the potential for relapse after successful treatment of panic disorder. Using non-invasive methods, we will obtain measures of cardiovascular and respiratory function in panic disorder patients along with a rigorous historical assessment of stressful life events. We will then use a combination of cognitive behavioral therapy and the antidepressant sertraline, both with well-validated efficacy for the treatment of panic disorder, and obtain repeated stress, cardiovascular, and respiratory measures during and after such treatment. The acute treatment phase is 3 months, the maintenance treatment phase is another 3 months, and the follow-up, no-treatment phase is 12 months. This investigation will enable us to test whether patients with panic disorder are vulnerable to the impact of stressful life events and what are the relationships with cardiovascular and respiratory function and panic relapse before, during, and after treatment. These relationships may offer important data for directing treatment approaches and allowing clinicians to test for vulnerability to panic disorder.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。惊恐障碍的病因仍不清楚。然而，来自神经科学对恐惧的研究和临床焦虑研究的数据表明，恐慌症可能是由基因决定的大脑恐惧通路的超敏反应和压力性生活事件的影响相结合来解释的。动物和人类研究也有大量证据表明，压力性生活事件会影响大脑恐惧通路的功能，并与恐慌症的发展，发作和复发有关。我们先前已经证明了惊恐障碍患者的心血管和呼吸功能指标明显异常。心脏和肺的控制受到大脑中参与对压力的反应和焦虑发展的区域的影响。我们现在计划调查紧张的生活事件，大脑对心血管和呼吸功能的控制，以及成功治疗惊恐障碍后复发的可能性之间的关系。使用非侵入性的方法，我们将获得惊恐障碍患者心血管和呼吸功能的测量结果，同时沿着对应激性生活事件的严格历史评估。然后，我们将使用认知行为疗法和抗抑郁药舍曲林的组合，两者都具有良好的疗效，用于治疗惊恐障碍，并在治疗期间和之后获得重复的压力，心血管和呼吸措施。急性治疗期为3个月，维持治疗期为另外3个月，随访期为12个月。这项研究将使我们能够测试惊恐障碍患者是否容易受到压力性生活事件的影响，以及治疗前、治疗中和治疗后与心血管和呼吸功能以及惊恐复发的关系。 这些关系可能为指导治疗方法和允许临床医生测试恐慌症的脆弱性提供重要数据。